Billionaire Profile
Sun Piaoyang
Global Rank
#251

Image: Unsplash Contributor | Unsplash License | via Unsplash

Sun Piaoyang

CEO, Pharmaceuticals
CHINA
Real-Time Net Worth
$12.393B
Estimated based on Pharmaceuticals stock value as of April 20, 2026
+0.02% (24h)
Age
67
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
CHINA

Biography

Sun Piaoyang, a prominent figure in the Chinese pharmaceutical industry, is the chairman of Jiangsu Hengrui Medicine, a leading producer of anti-infection and cancer medications. Born in 1958, he holds degrees from China Pharmaceutical University and Nanjing University. Under his leadership, Hengrui has transformed into a global pharmaceutical powerhouse, driving significant investments in research and development and achieving numerous breakthroughs in cancer treatment and other critical areas. With an estimated net worth of $12.0 billion, Sun has solidified his position as a key player in the healthcare sector, known for his commitment to innovation, patient-centered care, and sustainable growth.

Fact Checked
Verified by Editorial Team
Live Data
Updated 4/20/2026

Wealth Over Time

In-Depth Profile

Early Life and Education

Sun Piaoyang was born in 1958 in Lianyungang, China. He demonstrated exceptional academic abilities early on. He earned a bachelor's degree from China Pharmaceutical University and a doctoral degree from Nanjing University. His education laid the foundation for his successful career in the pharmaceutical industry.

Rise to Success

Sun Piaoyang began his career at the state-run Lianyungang Pharmaceutical Factory. In 1990, at the age of 32, he took over the company, which later became Jiangsu Hengrui Medicine. Under his leadership, Hengrui transformed from a small, state-owned factory into one of China's largest pharmaceutical companies. He spearheaded a shift towards innovation and research, particularly in oncology and cardiovascular treatments. The company's focus on research and development significantly boosted its market value.

Key Business Strategies

Sun Piaoyang's strategy focused on innovation and expanding into high-demand areas. He increased investments in research and development, setting Hengrui apart from other pharmaceutical companies in China. He led Hengrui to focus not only on manufacturing generic drugs but also on developing innovative treatments, particularly in oncology and cancer therapies. Sun also emphasized patient-centered innovation, aiming to address critical medical needs, especially for diseases like cancer. He also promoted global expansion and strategic partnerships, including securing international approvals for key medicines.

Philanthropy

Sun Piaoyang and his wife, Zhong Huijuan, were featured on the Hurun Philanthropy List in 2019 for their contributions to medical aid.

Career Milestones

1990

Took over Jiangsu Hengrui Medicine

Became the head of the formerly state-led Jiangsu Hengrui Medicine, transforming it into a leading pharmaceutical company.

2000

Jiangsu Hengrui Medicine went public

Led the firm to go public in Shanghai, boosting the company's financial standing and positioning it as a leading player.

2025

Led the firm to complete a Hong Kong listing

The listing raised $1.3 billion.

Philanthropy & Social Impact

Medical Aid

Medical Aid

Unknown

Sun Piaoyang and his wife Zhong Huijuan were featured on the Hurun Philanthropy List in 2019 for their contributions to medical aid.

Business Philosophy & Leadership

Leadership Principles

Innovation

Sun emphasizes innovation, directing significant resources into research and development to build a foundation for long-term success.

Patient-Centered Innovation

He believes in addressing critical medical needs by pushing the bounds of pharmaceutical science, especially for diseases like cancer.

Global Expansion

Sun promotes sustainable growth through global expansion and strategic partnerships.